Loading organizations...
I am currently unable to fetch full web page content due to repeated rate limiting errors (429 Too Many Requests) from the fetch_page tool. This prevents me from conducting the thorough research necessary to gather evidence for the company profile as specified, particularly for details like founder names, specific product capabilities, and the company's vision from official sources. Therefore, I cannot generate the requested company profile at this time.
Opio has raised $300K across 1 funding round.
Opio has raised $300K in total across 1 funding round.
Opio has raised $300K across 1 funding round. Most recently, it raised $300K Seed in January 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2021 | $300K Seed | — | AUC Angels | Announced |
Opio has raised $300K in total across 1 funding round.
Opio's investors include AUC Angels.
Opio Connect is a healthcare technology company founded in 2019 that develops robotic automation systems for opioid treatment programs (OTPs), primarily addressing the opioid crisis through efficient methadone dose preparation.[1][3][4] Its flagship product, ZING (also referred to as Bodhi in some contexts), is a robotic machine that automates measuring, bottling, capping, sealing, labeling, and photographing up to 28 doses of liquid methadone in just 4 minutes—4x faster than manual processes—helping OTPs combat nursing and pharmacist shortages while expanding patient access amid the fentanyl epidemic.[1][3][4] The company serves OTPs and satellite clinics across North America, solving labor-intensive tasks that divert staff from patient care, with $2.75M raised to date and positive customer feedback on efficiency and compliance.[1][4]
Opio Connect targets the rapidly growing opioid use disorder (OUD) treatment market, projected to double from $3.1B in 2023 to over $6B by 2030, by enabling remote service delivery, improving retention, and ensuring equitable access to methadone—the most effective treatment for fentanyl addiction.[3][4]
Opio Connect was co-founded in 2019 by Lanea George (née Norbeck), a nurse and board-certified clinical pharmacist with expertise in OUD care and healthcare technology, and Mike Pokorny, an engineer who designed patented niche electric motors.[1][3] The idea emerged from George's hospital experience with manual methadone dosing amid nursing shortages; in 2019, she and Pokorny brainstormed automation using off-the-shelf parts for pouring, sealing, labeling, and capping liquid methadone.[1] Norbeck quit her job in 2020, and they officially launched Opio Connect in January 2021, quickly developing ZING, which leverages robotics to handle compliance-heavy tasks in OTPs.[1][3]
Early traction included filing 4 patents in drug rehabilitation, health informatics, and infrared technology, securing $2.75M in funding (last round $900K about a year ago), and gaining adoption in OTPs for its speed and reliability.[1][3][4]
(Note: A separate, smaller AI consultancy named Opio Inc. exists in Los Angeles but lacks connection to this healthcare-focused entity and minimal public details.[2])
Opio Connect rides the opioid crisis wave, where fentanyl drives OUD as the fastest-growing U.S. healthcare sector and #1 killer of ages 18-45, demanding scalable methadone delivery amid provider shortages.[3][4] Timing aligns with post-2023 market doubling to $6B+ by 2030 and tech's push into healthcare automation, filling gaps left by outdated OTP systems reliant on manual labor.[1][3] Favorable forces include regulatory emphasis on OUD access, nursing crises, and robotics adoption in compliance-heavy fields; it influences the ecosystem by enabling OTP expansion, remote care (e.g., correctional facilities), and data-driven quality like ATLAS integration from co-founders' prior work.[1][3][4]
Opio Connect is poised for acceleration with recent funding, patent portfolio, and ZING's validated efficiency in real OTPs, potentially capturing share in the exploding OUD market.[1][4] Next steps likely include scaling deployments, AI-enhanced features for predictive dosing, and partnerships for nationwide satellite networks amid persistent fentanyl threats.[3][4] Evolving trends like workforce automation mandates and telehealth integration will amplify its influence, transforming OTPs from bottlenecked clinics to high-capacity care hubs—ultimately saving lives by making methadone as accessible as the crisis demands.[1][3]
